Publication Name	World Journal of Clinical Oncology
Manuscript ID	90087
Country	India

Received	2023-11-23 12:27
Peer-Review Started	2023-11-23 12:27
To Make the First Decision
Return for Revision	2024-01-12 06:09
Revised	2024-01-13 07:43
Second Decision	2024-02-20 02:52
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-02-20 07:11
Articles in Press	2024-02-20 07:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-03-05 06:33
Publish the Manuscript Online	2024-03-22 11:48

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma
Manuscript Source	Invited Manuscript
All Author List	Budhi Singh Yadav
ORCID	Author(s) ORCID Number Budhi Singh Yadav http://orcid.org/0000-0001-6185-4139
Funding Agency and Grant Number
Corresponding Author	Budhi Singh Yadav, MD, Professor, Department of Radiotherapy & Oncology, Post Graduate Institute of Medical Education & Research, Regional Cancer Centre, Sector 12, Chandigarh 160012, India. drbudhi@gmail.com
Key Words	Primary central nervous system lymphoma; High dose methotrexate; Zanubrutinib; Whole brain radiotherapy; Liquid biopsy
Core Tip	Primary central nervous system lymphoma is treated with high dose methotrexate induction followed by consolidation with whole-brain radiotherapy or autologous stem cell transplant. Depending on the general condition and disease status of these patients they can be offered maintenance therapy. Zanbrutinib may be offered to these patients for maintaining the response to primary treatment.
Publish Date	2024-03-22 11:48
Citation	Yadav BS. High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma. World J Clin Oncol 2024; 15(3): 371-374
URL	https://www.wjgnet.com/2218-4333/full/v15/i3/371.htm
DOI	https://dx.doi.org/10.5306/wjco.v15.i3.371

Full Article (PDF)	WJCO-15-371-with-cover.pdf
Manuscript File	90087_Auto_Edited-YJP.docx
Answering Reviewers	90087-Answering reviewers.pdf
Audio Core Tip	90087-Audio core tip.opus
Conflict-of-Interest Disclosure Form	90087-Conflict-of-interest statement.pdf
Copyright License Agreement	90087-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	90087-Language certificate.pdf
Peer-review Report	90087-Peer-review(s).pdf
Scientific Misconduct Check	90087-Bing-Li L-2.png
Scientific Editor Work List	90087-Scientific editor work list.pdf
CrossCheck Report	90087-CrossCheck report.pdf
CrossCheck Report	90087-CrossCheck.png